The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
Novo Nordisk's new Wegovy pill has exploded onto the scene, racking up over 26,000 prescriptions in just its second full week. This needle-free GLP-1 option signals a shift in obesity treatment. Discover the data, science, and patient implications behind this rapid uptake.
The UK's MHRA has updated guidance on a small but serious risk of acute pancreatitis linked to popular GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro. With over 1.6 million users, understanding symptoms and reporting is crucial. This guide breaks down the latest data, risks, and management strategies.
GLP-1 medications like Ozempic and Wegovy have transformed weight management, but rising lawsuits highlight serious side effects like gastroparesis and vision loss. This guide breaks down the science, risks, and strategies for safe use. Learn how to monitor symptoms and integrate lifestyle changes effectively.
GLP-1 medications like Ozempic and Wegovy promise dramatic weight loss, but new studies reveal a catch: most users regain weight within 1-2 years of stopping. High costs and side effects add to the burden, prompting interest in permanent alternatives. Learn the facts to make informed choices for your metabolic health.
Noticeable weight loss often leads to whispers: 'Are you on Ozempic?' GLP-1 medications like Ozempic and Wegovy are transforming bodies and conversations. Learn when it's appropriate to ask, drawing from medical experts and real patient experiences.
Over 11,600 people in Norfolk and Waveney may soon access Mounjaro on the NHS for weight loss. This guide breaks down eligibility, timelines, and clinical evidence behind tirzepatide's effectiveness. Learn how this dual GLP-1/GIP agonist stands out in metabolic health.
Ozempic has transformed weight loss, but is it too good to be true? Galway author Aimee Donnellan's 'Off the Scales' uncovers the science, overlooked pioneers, and real patient stories behind GLP-1 injections. Discover the benefits, serious risks like muscle loss, and what happens when you stop.
Alzheimer's disease may be more than just amyloid plaques—emerging evidence points to brain insulin resistance as a core driver, earning it the label 'Type 3 diabetes.' A recent Polish study uncovers how impaired insulin signaling starves neurons of energy and accelerates toxic protein buildup. Discover the science and potential therapies like GLP-1 agonists that could change the game.
Stopping Ozempic or Wegovy often leads to significant weight regain within 1-1.5 years, reversing gains in blood sugar, pressure, and cholesterol. Experts explain the science behind this, from metabolic adaptation to surging appetite. Understand how to approach GLP-1 therapy for long-term success.
